Otenabant is primarily researched for its potential application in the treatment of obesity and related metabolic disorders. It functions as a cannabinoid receptor antagonist, specifically targeting the CB1 receptor, which is involved in regulating appetite and energy balance. By blocking these receptors, it may help reduce food intake and promote weight loss. Additionally, Otenabant has been studied for its potential role in managing conditions such as type 2 diabetes and cardiovascular diseases, as obesity is a significant risk factor for these ailments. However, its development has faced challenges due to concerns about side effects, particularly those related to psychiatric and neurological effects. Research continues to explore its therapeutic benefits while addressing safety concerns.